One Health and veterinary biologics — the growing recognition that human health, animal health, and environmental health are inextricably interconnected — with veterinary biologics playing a critical role in preventing zoonotic disease transmission, containing pandemic threats at their animal source, and providing the comparative medicine research models that advance human therapeutic development — creating the global health security rationale for increased veterinary biologics investment within the Veterinary Biologics Market, with WHO, FAO, and OIE (World Organisation for Animal Health) collectively advancing the One Health framework that positions veterinary biologics as essential components of global pandemic preparedness.

Zoonotic disease prevention through veterinary vaccination — the pandemic prevention value — the majority of emerging infectious diseases (seventy to seventy-five percent — Jones 2008 Nature) being zoonoses originating in animal reservoirs — including SARS-CoV-2 (bat origin), H5N1 and H1N1 influenza (avian and swine origin), Nipah virus (bat origin), Ebola (bat-animal-human spillover), Marburg, MERS-CoV (camel origin), and rabies (domestic and wild animal origin). Veterinary biologics directly interrupting zoonotic transmission chains: canine rabies vaccines eliminating domestic dog rabies reservoir (WHO target: zero human rabies deaths from dog transmission by 2030, primarily through mass dog vaccination); avian influenza vaccines preventing poultry-human transmission; brucellosis vaccination reducing bovine-human transmission; and research-stage wildlife oral vaccine programs (raccoon rabies — Raboral V-RG; SARS-CoV-2 vaccines for mink and white-tailed deer).

H5N1 avian influenza — the current veterinary biologics emergency — the ongoing H5N1 highly pathogenic avian influenza (HPAI) pandemic in poultry and wildlife (affecting domestic poultry in forty-plus countries, wild birds globally, marine mammals, and documented cattle infection in the US in 2024) representing the most urgent current zoonotic threat where veterinary biologics play an immediate public health security role. The USDA's emergency H5N1 poultry vaccine stockpile development; the debate over national poultry vaccination programs (France implementing; US historically using stamping-out approach; weighing vaccination versus trade restrictions); and the cattle H5N1 outbreak vaccination research — collectively demonstrating the intersection of veterinary biologics with international trade policy, pandemic preparedness, and human influenza pandemic risk management.

Veterinary biologics as pandemic preparedness infrastructure — the global health security investment case — the Biden Administration's National Pandemic Preparedness Plan and the G7 100 Days Mission (developing safe and effective vaccines within one hundred days of pandemic declaration) both implicitly requiring robust veterinary surveillance and veterinary biological response capability as the animal-to-human interface monitoring and intervention layer in pandemic preparedness. The Wellcome Trust and Gates Foundation investments in zoonotic disease surveillance and veterinary biologics research — recognizing that pandemic prevention at the animal source is dramatically more cost-effective than post-emergence pandemic response. The WHO's Global Antimicrobial Resistance Action Plan (GAMAP) and the FAO's Global Action Plan on Antimicrobial Resistance both explicitly including veterinary vaccine promotion as AMR prevention strategies.

Do you think the COVID-19 pandemic and the ongoing H5N1 HPAI threat will result in sustained, substantially increased government investment in veterinary biologics research, development, and production capacity — treating veterinary biologics as critical pandemic preparedness infrastructure — or will pandemic preparedness investment focus primarily on human vaccine platforms while veterinary biologics remain relatively underfunded relative to their pandemic prevention value?

FAQ

How is the One Health approach being implemented in regulatory frameworks for veterinary biologics globally? One Health regulatory implementation: international organizations: WHO, FAO, OIE Tripartite: One Health framework; coordinated animal and human health surveillance; zoonotic disease monitoring; antimicrobial resistance One Health action plan; OIE (WOAH) standards: veterinary biologics standards; vaccine quality standards; international trade requirements; OIE Terrestrial Animal Health Code: vaccination guidelines by disease; US regulatory implementation: USDA-FDA collaboration: zoonotic disease oversight; FDA: human biologics; USDA: animal biologics; joint programs: H5N1 response; zoonotic disease; DHS: biodefense; HPAI response coordination; CDC-USDA collaboration: One Health Office; zoonotic surveillance; National Veterinary Stockpile (NVS): USDA managed; emergency vaccine reserve; FMD, ND, HPAI vaccines; EU One Health implementation: European Food Safety Authority (EFSA): food safety + animal health; EMA CVMP: veterinary medicines committee; ECDC (European Centre for Disease Prevention and Control): human infectious disease; One Health Network: European coordination; AMR implementation: EU Action Plan on AMR: veterinary biologics as tool; European AMR monitoring (ESVAC); national initiatives: UK: APHA (Animal and Plant Health Agency): veterinary biologics; UK Health Security Agency (UKHSA): human; joint zoonosis response; Australia: DAFF (Department of Agriculture, Fisheries and Forestry); TGA (Therapeutic Goods Administration); joint HPAI response; Japan: MAFF (Ministry of Agriculture, Fisheries and Food); MHLW (Ministry of Health, Labour and Welfare); One Health Council; emerging markets: Africa: AU-IBAR (African Union Interafrican Bureau for Animal Resources); PANVAC (Pan African Veterinary Vaccine Centre): continental vaccine quality; One Health Africa: building surveillance; One Health implementation challenges: siloed regulatory systems: different agencies, different standards; funding: veterinary biologics underfunded versus human; data sharing: animal surveillance informing human policy; international coordination: trade restrictions complicating vaccination programs.

What is the antimicrobial resistance (AMR) reduction impact of veterinary biologics programs? Veterinary biologics and antimicrobial resistance: mechanism of AMR reduction: vaccines prevent infections: reducing antibiotic treatment need; fewer infections = fewer antibiotic courses = less selection pressure; healthier animals: fewer opportunities for resistant organism development; specific examples: Norwegian salmon: vaccine program eliminating antibiotic use; one thousand-fold antibiotic reduction (1987-2018); fisheries model for AMR reduction through vaccination; pig respiratory disease (PRRS, PCV2): vaccination reducing secondary bacterial infection requiring antibiotics; cattle BRD: vaccination reducing metaphylaxis antibiotic programs; swine dysentery: vaccination reducing antibiotic treatment; poultry: vaccination programs enabling antibiotic reduction; global AMR economic impact: AMR: ten million deaths annually by 2050 (WHO projection); economic cost: one hundred trillion dollars globally; veterinary AMR contribution: significant; livestock antibiotic use: fifty to eighty percent of global antibiotic volume (countries vary); AMR in veterinary pathogens: resistance in livestock bacteria; spillover to human pathogens; quantifying vaccine AMR benefit: WHO: vaccines potentially preventing seven hundred thousand deaths annually from AMR by 2030; modeling studies: Taylor 2021 (Lancet Infectious Diseases): vaccines reducing AMR need; economic analysis: AMR economic return on veterinary vaccine investment: twenty to forty times; farm-level: reducing treatment cost; system-level: reducing AMR development; regulatory response: EU: restrictions on antibiotic use in livestock; veterinary prescription requirements; ban on preventive/growth promotion antibiotics (2022); driving vaccine adoption; UK: National Action Plan on AMR: veterinary vaccination component; China: AMR reduction target: veterinary biologics investment; US: FDA Guidance 213: veterinary antibiotic use reduction; voluntary; veterinary biologics role recognized; industry response: Zoetis, Elanco, Boehringer: AMR stewardship programs; vaccine-antibiotic reduction connection; market opportunity: AMR reduction: vaccine demand driver; regulatory incentive; farmer economic benefit.

#OneHealth #VeterinaryBiologicsMarket #ZoonoticDisease #AMRreduction #VeterinaryPandemicPreparedness